The imaging technique at the heart of the study, positron emission tomography combined with computed tomography, has become a cornerstone of modern cancer care. Patients receive an injection of [18F]-fluorodeoxyglucose, a radioactive glucose analog that is avidly taken up by metabolically active cells. Because cancer cells typically consume glucose at a far higher rate than healthy tissue, they light up on the resulting images, allowing physicians to visualize both the primary tumor and any spread to lymph nodes or distant organs. The PET component reveals metabolic activity, while the CT component provides detailed anatomical context, and the fusion of the two gives clinicians a map of where active disease resides in the body.

In the standard workflow for locally advanced cervical cancer, PET-CT is used twice: once before treatment begins, to establish the stage of the disease, and again several weeks after chemoradiotherapy has concluded, to assess how well the cancer responded. The Swedish team set out to determine whether the information gathered at that second time point could do more than simply confirm whether the tumor had shrunk. They wanted to know whether the pattern of metabolic response could serve as a genuine prognostic instrument, capable of stratifying patients into distinct risk categories that would justify different follow-up strategies or, potentially, additional interventions.

To quantify treatment response, the researchers extracted three complementary parameters from every scan. The first and most widely used is SUVmax, the maximum standardized uptake value, which reflects the peak glucose metabolism within the most active region of a lesion. The second is metabolic tumour volume, or MTV, which measures the total physical volume of tissue exhibiting abnormally high FDG uptake. The third is total lesion glycolysis, or TLG, which combines volume and intensity into a single figure representing the overall metabolic burden carried by the disease. Each parameter captures a different dimension of tumor biology, and the team analyzed all three separately to see whether the more computationally demanding volume-based measures offered any advantage over the simple maximum uptake value.

Using these parameters, the investigators classified each patient’s post-treatment response into one of four categories adapted from established response criteria. A complete metabolic response, or CMR, meant the total resolution of abnormal FDG uptake in all lesions, essentially signaling that no metabolically active cancer could be detected anywhere in the scanned field. A partial metabolic response, or PMR, was defined as a reduction of more than 25 percent in SUVmax, MTV or TLG, indicating that disease remained but had been substantially weakened. Progressive metabolic disease, or PMD, was declared when uptake increased by more than 25 percent or when new FDG-avid lesions appeared, a clear sign that the treatment had failed to contain the cancer. Patients who fit none of these categories were classified as having stable disease. Because the number of events in the PMR and stable disease groups was limited, the researchers combined them into a single intermediate group for statistical analysis.

The results were striking. Taking patients with complete metabolic response as the reference group, those with partial response or stable disease faced roughly 1.2 times the odds of experiencing a recurrence, a modest but measurable elevation in risk. Far more dramatic was the picture for patients whose disease progressed: their odds of recurrence were 1.7 times higher when response was assessed by SUVmax, and 1.8 times higher when assessed by MTV or TLG. In other words, a scan showing growing or newly emerged metabolically active disease after treatment was a red flag that recurrence was substantially more likely, regardless of which of the three parameters was used to make the call.

The survival analysis carried an even starker message. Patients in the intermediate response group had a hazard ratio for death of 4.0 when response was measured by SUVmax, meaning their risk of dying during the follow-up period was four times that of patients who achieved a complete metabolic response. When MTV or TLG served as the response metric, the hazard ratio for this intermediate group was 2.9. For patients with progressive metabolic disease, the hazard ratio soared to 16.0 across all three parameters, a sixteen-fold increase in mortality risk compared with complete responders. The concordance index, a statistical measure of how well a model discriminates between patients with different outcomes, reached 0.84 for SUVmax-based models and 0.86 for models built on MTV or TLG, values that indicate strong predictive performance for any prognostic tool in oncology.

Perhaps the most consequential finding of the study is what it did not find: no meaningful superiority of the sophisticated volume-based parameters over the simple maximum uptake value. MTV and TLG require semi-automated segmentation of tumor volumes and considerably more computational processing, and some researchers have argued that their added information content should translate into better prognostic power. In this cohort, however, the three parameters performed in a nearly identical fashion, with concordance indices differing by only two hundredths. For clinical practice, this is genuinely good news, because it suggests that the prognostic value of post-treatment PET-CT can be unlocked using a parameter that is already routinely reported by nuclear medicine departments worldwide, without the need for new software, additional training or workflow changes.

The implications for patient management are considerable. Patients who achieve a complete metabolic response could potentially be spared intensive surveillance, receiving standard follow-up with the reassurance that their statistical outlook is excellent. Those with partial or stable metabolic response, whose risk is elevated but not extreme, might benefit from closer imaging intervals and a lower threshold for biopsy or salvage interventions. Patients showing progression on the post-treatment scan represent the group with the most urgent need for attention, and the sixteen-fold hazard ratio suggests that early escalation of care, whether through additional systemic therapy or enrollment in clinical trials of novel agents, could be life-extending for this small but high-risk population. The study also reinforces the value of performing a post-treatment PET-CT at all, since the metabolic information it provides clearly carries prognostic weight beyond anatomical assessment alone.

As with all retrospective single-center analyses, the findings come with caveats. The 133 patients were treated at a single Swedish institution, and the classification thresholds, including the 25 percent change criteria, were drawn from established response frameworks rather than derived de novo. Prospective validation in larger and more diverse cohorts will be needed before response category can be formally incorporated into treatment guidelines. Nevertheless, the strength and consistency of the associations, spanning recurrence risk, overall survival and three independent metabolic parameters, make a compelling case that the post-treatment FDG-PET/CT scan is far more than a formality. It is, in effect, a crystal ball of glucose metabolism, offering each patient and her medical team an early, individualized forecast of the road ahead, and pointing the way toward a future in which follow-up care for cervical cancer is tailored not to the average patient but to the biology revealed on a single scan.

Subject of Research: FDG-PET/CT-based treatment response assessment as a predictor of recurrence and survival in locally advanced cervical cancer

Article Title: FDG-PET/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer

Article References: Markus, M., Sartor, H., Bjurberg, M., Minarik, D., & Trägårdh, E. (2026). FDG-PET/CT-based treatment response predicts recurrence and overall survival in locally advanced cervical cancer. BMC Medical Imaging, 26(1), Article 458. https://doi.org/10.1186/s12880-026-02772-8

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02772-8

Keywords: FDG-PET/CT, cervical cancer, treatment response, SUVmax, metabolic tumour volume, total lesion glycolysis, recurrence, overall survival, radiotherapy, nuclear medicine, predictive medicine, oncology

The clinical benchmark for staging idiopathic pulmonary fibrosis is the GAP score, an acronym drawn from the variables it incorporates: gender, age, and physiology, the latter captured through lung function tests such as forced vital capacity and the transfer factor for carbon monoxide. The GAP score is a powerful and convenient tool, but it is fundamentally static. It describes the damage that has already accumulated; it says nothing about the biological activity of the disease at the level of the tissue itself. That distinction matters because fibrosis is not merely a passive scar. In active disease, fibroblasts proliferate, inflammatory cells infiltrate, and remodeling processes consume energy, and all of that cellular work demands fuel, principally glucose.

This metabolic hunger is precisely what fluorodeoxyglucose exploits. The radiotracer is a glucose analog labeled with fluorine-18, and once injected it is taken up by metabolically active cells, where it becomes trapped after phosphorylation and emits positrons that the PET scanner detects. In oncology, this principle underpins the familiar maximum standardised uptake value, or SUVmax, a number that quantifies the hottest spot of tracer accumulation within a lesion. The Gdańsk team asked a deceptively simple question: could the same measurement, applied not to tumors but to fibrotic lung parenchyma, serve as a window into the aggressiveness of pulmonary fibrosis?

To find out, the researchers turned to a cohort of thirty patients with idiopathic pulmonary fibrosis who had undergone fluorodeoxyglucose PET/CT for suspected comorbid disease, most often to rule out malignancy. This is a common clinical scenario, since patients with pulmonary fibrosis carry an elevated risk of lung cancer, and the retrospective design allowed the team to mine scans that had already been acquired for other reasons. The researchers measured raw SUVmax values within the fibrotic regions of the lung and compared those values against each patient’s GAP score calculated at the time of the scan. Because uptake values and severity scores are not normally distributed in a sample of this size, they used Spearman’s rank correlation coefficient, a non-parametric statistic that assesses whether two variables tend to increase together without assuming a linear relationship.

The answer was a qualified yes. The correlation between GAP score and fibrotic-lung SUVmax was positive and statistically significant, with a Spearman coefficient of 0.448 and a p-value of 0.013. In plain terms, patients whose lungs burned through more glucose on the scan tended to be the patients whose disease was already more advanced by conventional clinical criteria. A coefficient of 0.448 represents a moderate association, not a perfect one, and the authors are careful to frame the finding as exploratory. Yet the implication is striking: a molecular imaging measurement, taken from a single scan session, appears to carry information that overlaps with, and potentially extends beyond, the physiologic staging that clinicians currently rely upon.

The more provocative part of the study concerns outcomes. The researchers split their cohort into high and low metabolic activity groups using a median split of the SUVmax values, set at 2.53 for the full cohort of thirty patients and at 2.75 for the nineteen patients who were receiving antifibrotic therapy, the modern standard of care with drugs such as the tyrosine kinase inhibitor nintedanib. They then compared progression-free survival and overall survival between the groups using the Mantel-Cox log-rank test, the standard survival analysis method that compares the hazard of an event over time between two populations. In the antifibrotic-treated subgroup, patients with high uptake in their fibrotic lesions showed a median progression-free survival of twenty-five months, exactly half the fifty months observed in the low-uptake group, corresponding to a hazard ratio of 3.68.

Here the statistical caution becomes essential. The confidence interval for that hazard ratio stretched from 0.74 to 18.43, a range that crosses the value of 1.0, meaning the result cannot be distinguished from chance, and the log-rank p-value of 0.089 fell short of the conventional threshold of 0.05. The authors are transparent about this: the survival signal is a hypothesis-generating observation, not a proven predictor. But the pattern is biologically coherent and clinically tantalizing. A hazard ratio approaching four, even with wide uncertainty, suggests that with a larger sample the association could harden into something actionable. If metabolic activity in fibrotic lung truly doubles the pace of progression despite antifibrotic drugs, that information could reshape decisions about monitoring frequency, transplant referral timing, and enrollment into clinical trials of new therapies.

The study’s limitations are the natural consequences of its design. Thirty patients is a small sample, and the scans were acquired for indications unrelated to fibrosis staging, which introduces selection bias even as it offers a glimpse of real-world imaging. The retrospective framework, approved by the Bioethics Committee of the Medical University of Gdańsk with the consent requirement waived, means the researchers could not standardise when or why each scan was performed. SUV measurements are also sensitive to technical factors such as patient blood glucose levels, uptake time, and scanner calibration, all of which complicate comparisons across individuals. The authors themselves conclude that larger prospective studies are required before molecular imaging can be declared an additive prognostic tool in idiopathic pulmonary fibrosis.

Even so, the conceptual advance is worth savoring. For decades, the assessment of fibrotic lung disease has rested on structural and functional endpoints: how much the lung can hold, how well oxygen crosses the membrane, how the tissue looks on high-resolution CT. These measures capture the aftermath of disease. Metabolic imaging, by contrast, offers something closer to a live readout of the pathological process itself, the cellular furnace that drives scarring forward. Previous research has linked fluorodeoxyglucose uptake in the lung to inflammatory and proliferative activity in interstitial disease, and the Gdańsk findings now tie that signal to a validated severity index and to survival trajectories in a treated population.

The road from exploratory correlation to clinical utility is long, and most imaging biomarkers that show promise in small retrospective series never reach the clinic. But the logic of this study points toward a future in which a patient’s PET scan does more than exclude cancer. It could quantify how ferociously their fibrosis is burning, stratify them into risk groups that GAP scores alone cannot resolve, and identify the patients most likely to benefit from intensified therapy or novel antifibrotic agents. For a disease that kills most of those it afflicts within a few years of diagnosis, any tool that reveals the fire beneath the scar, before the lung has irreversibly stiffened, would represent a genuine leap forward. This study is an early, cautious step in that direction, and its authors have mapped the path that the next, larger studies must walk.

Subject of Research: Association between fibrotic-lung FDG-PET uptake and disease severity and outcomes in idiopathic pulmonary fibrosis

Article Title: Association of fibrotic-lung 18F-FDG uptake with GAP severity and clinical outcomes in idiopathic pulmonary fibrosis: an exploratory retrospective study

Article References: Ward, C., Oppmann-Ward, A., Wilczynski, S., Korneliussen, J., Żegleń, S., Rogoza, K., & Cytawa, W. (2026). Association of fibrotic-lung 18F-FDG uptake with GAP severity and clinical outcomes in idiopathic pulmonary fibrosis: an exploratory retrospective study. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02856-5

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02856-5

Keywords: idiopathic pulmonary fibrosis, FDG-PET/CT, SUVmax, GAP score, pulmonary fibrosis, nuclear medicine, interstitial lung disease, progression-free survival, antifibrotic therapy, molecular imaging, lung fibrosis, prognosis

The research team, led by Yanmei Han and corresponding authors Zairong Gao and Xiao Zhang, set out to address a well-recognized gap in lymphoma prognostication. Existing risk stratification systems for MALT lymphoma, including the MALT lymphoma International Prognostic Index, rely on clinical parameters such as age, disease stage, and lactate dehydrogenase levels, but they do not incorporate information from metabolic imaging. That omission matters, because fluorodeoxyglucose positron emission tomography combined with computed tomography captures something that blood tests and pathology slides cannot: the glucose appetite of the tumor in living tissue. The maximum standardized uptake value, or SUVmax, quantifies how avidly the most active region of a lesion consumes the radiolabeled glucose analog, providing a whole-body metabolic fingerprint of the disease at baseline.

To build their model, the investigators retrospectively analyzed 98 patients with histologically confirmed MALT lymphoma who underwent baseline FDG PET/CT scanning between January 2020 and December 2024. From the pool of available clinical, laboratory, pathological, and imaging measurements, they assembled 17 candidate predictors. Rather than forcing all of them into a regression equation, the team applied least absolute shrinkage and selection operator regression, a statistical technique known as LASSO that penalizes model complexity and drives the coefficients of uninformative variables to zero. Ten-fold cross-validation was used to tune the procedure, meaning the data were repeatedly split so that the variable selection would not simply memorize the quirks of one particular sample.

Out of the 17 candidates, five variables survived the LASSO filter: patient age, the primary site of disease, SUVmax, the Ki-67 proliferation index, and Eastern Cooperative Oncology Group performance status. Each of these carries a plausible biological story. Age and performance status reflect the resilience of the patient and the aggressiveness of the clinical course. Ki-67 measures the fraction of tumor cells actively dividing, a direct readout of proliferative drive. The primary disease site has long been associated with differing behaviors across MALT lymphoma locations, with gastric and non-gastric presentations following distinct trajectories. SUVmax, the sole imaging variable to make the cut, adds the metabolic dimension that conventional indices have ignored.

These five predictors were then combined in a multivariable Cox regression, the standard framework for modeling time-to-event outcomes such as progression-free survival. The result was distilled into a nomogram, a graphical scoring instrument that allows a clinician to assign points to each patient characteristic and read off an estimated probability of remaining progression-free. On the data used to build the model, the five-variable score achieved a concordance index of 0.814, with a 95 percent confidence interval of 0.738 to 0.891. The concordance index, or C-index, expresses the probability that a patient who progresses earlier is correctly assigned a higher risk score than a patient who progresses later, with 0.5 representing random guessing and 1.0 representing perfect ranking.

The authors were careful not to stop at that flattering apparent figure. Apparent performance is notoriously optimistic, because the same data that build a model inevitably flatter it. To correct for this, the team ran a full-pipeline bootstrap procedure with 500 resamples, in which the entire modeling process, from variable selection onward, was repeated on each resampled dataset. This approach estimates how much the model’s measured accuracy is inflated by chance fitting, and the optimism-corrected C-index settled at 0.740, with a 95 percent uncertainty interval of 0.662 to 0.757. In practical terms, the model retains moderate discriminative ability after accounting for statistical overfitting, a level of honesty that many published prognostic models never report.

Time-dependent receiver operating characteristic analysis added a temporal dimension to the evaluation. The area under the time-ROC curve was 0.766 at one year, 0.872 at two years, and 0.883 at three years, indicating that the model’s ability to separate patients who progress from those who remain in remission actually strengthens over the first few years of follow-up. That pattern is clinically meaningful for an indolent lymphoma, where the most consequential question is often not whether relapse will ever occur but whether it will arrive early enough to justify intensified surveillance or alternative first-line strategies.

Perhaps the most intriguing result emerged from an exploratory re-stratification exercise. The team focused on patients classified as intermediate risk by the MALT-IPI, the current standard prognostic index, and asked whether the new integrated model could split this apparently homogeneous group into meaningful subgroups. It could. Within the intermediate-risk category, the nomogram separated patients into lower-risk and higher-risk groups that showed clearly different observed progression-free survival. If confirmed in larger and independent cohorts, this finding suggests that metabolic imaging can refine the coarse resolution of existing clinical indices, potentially sparing lower-risk intermediate patients unnecessary treatment intensity while flagging higher-risk ones for closer monitoring.

The study’s limitations are those inherent to its design. It was retrospective, single-center, and modest in size, with 28 progression events among 98 patients, and the validation was internal rather than external. The authors themselves describe the risk separation within the intermediate-risk subgroup as exploratory. External validation on independent cohorts from different institutions and populations will be essential before the nomogram can influence routine clinical decisions. Nevertheless, the methodological rigor, including the full-pipeline bootstrap and the transparent reporting of optimism-corrected performance, sets a standard that prognostic modeling studies in oncology imaging do not always meet.

Beyond its immediate findings, the work signals a broader shift in how nuclear medicine and hematology are converging. FDG PET/CT has already transformed staging and response assessment in aggressive lymphomas, and quantitative metabolic parameters are increasingly being treated as biomarkers in their own right rather than as pictures for the radiologist’s eye alone. By demonstrating that a single imaging metric can stand alongside age, proliferation index, and performance status in a validated survival model, the Wuhan team provides a template for integrating molecular imaging into prognostic algorithms across indolent cancers. For patients with MALT lymphoma, the hope is that a routine baseline scan, already performed in many centers, will one day do double duty: mapping the disease and forecasting its course, so that the small minority destined for early progression can be identified while their options are still widest.

Subject of Research: An integrated FDG PET/CT and clinicopathological nomogram for predicting progression-free survival in MALT lymphoma

Article Title: Development and internal evaluation of an integrated [18F]FDG PET/CT-clinicopathological nomogram for predicting progression-free survival in MALT lymphoma

Article References: Han, Y., Zhang, Y., Wu, R., Hu, F., Gao, Z., & Zhang, X. (2026). Development and internal evaluation of an integrated [18F]FDG PET/CT-clinicopathological nomogram for predicting progression-free survival in MALT lymphoma. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02847-6

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02847-6

Keywords: MALT lymphoma, FDG PET/CT, nomogram, SUVmax, progression-free survival, prognosis, Ki-67 index, LASSO regression, Cox regression, bootstrap validation, MALT-IPI, nuclear medicine

The patient’s story began innocuously. He had been treated with rabbit anti-thymocyte globulin and cyclosporine between June and October 2024 for marrow hypoplasia, leaving him profoundly immunosuppressed and neutropenic, with absolute neutrophil counts hovering between 320 and 390 cells per microliter. A non-enhanced chest computed tomography scan performed at an outside facility showed consolidation in the right lung, and he was given empiric ciprofloxacin for presumed pneumonia. Notably, he had no fever and no respiratory symptoms at that stage, and laboratory markers including carcinoembryonic antigen, neuron-specific enolase, beta-D-glucan and Aspergillus antigen all came back unremarkable. In an immunocompromised host, however, consolidation is usually treated as infection until proven otherwise, and the initial workup proceeded along those lines.

The turning point came on Day 14, when a repeat non-enhanced chest CT showed marked worsening of the right lower lobe lesion, with a mixture of ground-glass opacity and consolidation, a new pleural effusion, and scattered nodules surrounded by halo signs. That radiologic pattern, in which a nodule is ringed by a rim of ground-glass attenuation, is classically associated with invasive pulmonary aspergillosis, although mucormycosis could not be excluded. A cough developed around the same time and a single fever of 38.1 degrees Celsius was recorded at admission, but the patient never required supplemental oxygen. Bronchoscopy on Day 15 revealed no endobronchial lesions, and the bronchoalveolar lavage fluid from the right anterior basal segment was xanthochromic, a yellowish discoloration that, in retrospect, signaled occult alveolar hemorrhage linked to infarction rather than the cloudy return typical of pneumonia.

Every microbiologic test came back negative. Bacterial and fungal cultures, galactomannan assays and viral polymerase chain reaction panels were all sterile, and a transbronchial lung biopsy showed only focal organizing pneumonia without fungal elements. Nevertheless, because the parenchymal disease was worsening, the clinical team initiated liposomal amphotericin B and piperacillin-tazobactam, a broad-spectrum antifungal and antibacterial combination. The lung lesion failed to improve. This disconnect between aggressive antimicrobial therapy and persistent radiologic disease should have been the first clear signal that the working diagnosis was wrong, and it set the stage for a more careful look at the pulmonary vasculature.

That look came indirectly. Concerned about the patient’s coexisting chronic kidney disease, clinicians obtained another non-enhanced chest CT on Day 20, which revealed a dilated main pulmonary artery, enlargement of the right-sided cardiac chambers and a pericardial effusion, a triad suggestive of pulmonary hypertension. A contrast-enhanced chest CT on Day 21 then delivered the answer: a low-attenuation filling defect in the right interlobar and lower lobar pulmonary arteries, with associated infarction of the lung tissue downstream. Anticoagulation was started immediately. Because the scan had not been performed with a dedicated pulmonary embolism protocol, CT pulmonary angiography was repeated on Day 27, showing that the filling defect persisted after a week of anticoagulation and had extended into the lobar branches. Its unilateral, expansile appearance raised a new and alarming possibility: pulmonary artery sarcoma, an exceptionally rare malignancy with an estimated incidence of only 0.001 to 0.03 percent.

Distinguishing a chronic organized thrombus from an intraluminal sarcoma is one of the classic dilemmas in pulmonary vascular imaging. Chronic thromboembolic pulmonary hypertension typically produces vessel narrowing or intraluminal webs, whereas sarcoma tends to appear as an expansile, lobulated mass that distends the artery. In this case, fluorodeoxyglucose positron emission tomography on Day 29 showed only mildly heterogeneous uptake within the lesion, with a maximum standardized uptake value of 2.9, a level that favored thrombus over tumor. Endobronchial ultrasound-guided transbronchial needle aspiration of the right lower lobe pulmonary artery, a technique highlighted in the report as a safe route for tissue acquisition, yielded whitish necrotic cores. Pathology described predominantly thrombotic material with only a few atypical cells, insufficient to exclude malignancy. Right heart catheterization confirmed precapillary pulmonary hypertension, and angiography demonstrated total occlusion of the right lower lobe pulmonary artery.

With the lesion persisting after nearly a month of anticoagulation and malignancy still on the differential, the team planned a pulmonary endarterectomy, a procedure that could serve as both treatment and definitive biopsy. Because the patient remained clinically stable without oxygen requirement or worsening breathlessness, the operation was scheduled electively. While awaiting surgery, however, his dyspnea gradually worsened and the pleural effusion grew, prompting readmission and an earlier operation on Day 87. Surgeons found extensive material filling the right pulmonary artery and dissected it distally into the lobar branches, consistent with level III disease in the UCSD surgical classification of endarterectomy findings. The decisive result came from histopathology: Brown and Brenn staining revealed Gram-positive cocci within the organizing thrombus, confirming a septic pulmonary artery thrombus. The patient later recalled a remote dental implant infection, a plausible source of the bacteremia that had seeded the vessel. He completed four weeks of ceftriaxone, and after an urgent re-exploration for postoperative bleeding, he recovered without further surgical complications.

The case is remarkable for what it lacked as much as for what it showed. A septic thrombus inside a major pulmonary artery would ordinarily be expected to produce overt sepsis or signs of infective endocarditis, yet this patient had essentially none of the classic systemic features. The report notes that septic pulmonary embolism can present with attenuated systemic manifestations, particularly in patients with prior antimicrobial exposure or immunosuppression, both of which applied here. Antibiotics given for the presumed pneumonia may have partially suppressed the inflammatory response, while the underlying immunosuppressive therapy blunted fever and other warning signs. The result was a vascular infection smoldering silently for weeks, masquerading first as pneumonia and then as an aggressive fungal process, and only unmasked when imaging of the pulmonary arteries was finally performed with contrast.

The authors distill several lessons that extend well beyond this single patient. Pulmonary consolidation that follows an atypical course or fails to respond to appropriate antimicrobials should prompt consideration of pulmonary infarction, and dedicated CT pulmonary angiography should be obtained early once a vascular etiology is suspected, rather than relying on non-enhanced or non-dedicated scans. A unilateral pulmonary artery filling defect that persists despite adequate anticoagulation, especially when accompanied by pulmonary hypertension, warrants evaluation for chronic thromboembolic disease and pulmonary artery malignancy. Metabolic imaging with FDG PET-CT and minimally invasive sampling through EBUS-guided needle aspiration can provide useful clues, but as this case demonstrates, they may remain non-diagnostic, and surgical pathology or endarterectomy may ultimately be required to settle the question.

For clinicians caring for the growing population of immunocompromised patients, the message is a sobering one. The xanthochromic bronchoalveolar lavage fluid, the early CT signs of pulmonary hypertension, and the relentless progression despite broad-spectrum therapy were all, in hindsight, pointing toward a vascular catastrophe rather than an infection. Recognizing those signals sooner could have shortened a diagnostic odyssey that stretched across nearly three months from first scan to definitive surgery. Septic organizing thrombus of the pulmonary artery remains a rare diagnosis, but as this case makes clear, it belongs on the differential for any immunocompromised patient whose lung lesion refuses to behave like pneumonia, and whose arteries tell a story the parenchyma has been hiding all along.

Subject of Research: Septic pulmonary artery thrombus causing pulmonary infarction in an immunocompromised patient

Article Title: Unilateral Pulmonary Artery Lesion in an Immunocompromised Patient

Article References: Lee, S., Lee, K. S., Jeong, D. Y., Lee, B., Lee, J., Jeong, D. S., Chang, S.-A., & Shin, S. H. (2026). Unilateral Pulmonary Artery Lesion in an Immunocompromised Patient. Respirology Case Reports, 14(10), Article e70778. https://doi.org/10.1002/rcr2.70778

Image Credits: AI Generated

DOI: 10.1002/rcr2.70778

Keywords: pulmonary artery thrombus, pulmonary infarction, immunocompromised, myelodysplastic syndrome, pulmonary hypertension, pulmonary endarterectomy, CT pulmonary angiography, FDG PET-CT, EBUS-TBNA, septic pulmonary embolism, pulmonary artery sarcoma, chronic thromboembolic disease

The research team, led by Le Song and Na Guo, with Weifang Zhang as corresponding author, combed through bone scintigraphy studies performed at their institution between 2019 and 2022. Among thousands of scans, they identified 66 patients who displayed focal uptake within the orbital region, an incidence of roughly 0.9 percent of all bone scans. That figure alone is informative: orbital uptake is uncommon, which is precisely why most physicians have lacked the large, longitudinally followed cohorts needed to say anything confident about it. By assembling 66 patients and evaluating 76 distinct orbital foci, the Beijing group created one of the first multi-modality portraits of this finding, combining planar bone scintigraphy with magnetic resonance imaging, computed tomography, fluorine-18 fluorodeoxyglucose positron emission tomography, and, crucially, follow-up imaging over many months.

The anatomical and morphological patterns that emerged were strikingly consistent. Of the 76 orbital foci, 61, or 80.3 percent, localized to the superior or lateral walls of the orbit, and 72, or 94.7 percent, appeared round in shape. Those two features, a predilection for the upper and outer orbital walls and a rounded contour, are exactly what one would expect from slow-growing, indolent processes such as fibrous dysplasia or other benign osseous variants, and exactly what one would not expect from the ragged, permeative architecture of metastatic deposits. Meanwhile, the extra-orbital findings in these patients told a separate story about why the scans had been ordered in the first place: five patients had bona fide skeletal metastases elsewhere, 34 showed degenerative changes, and 17 harbored other benign lesions.

The technical heart of the study lies in its quantitative analysis of the target-to-nontarget ratio, a standard measure in bone scintigraphy that compares tracer intensity in a suspicious focus with that in adjacent normal bone. In the 27 patients who underwent follow-up bone scintigraphy, at a median interval of 23.0 months, the median T/NT ratio drifted from 4.9 down to 3.7, a change that did not reach statistical significance, with a P value of 0.301. More telling than the ratio itself was the visual verdict: 25 of 28 lesions examined longitudinally appeared unchanged on side-by-side comparison, and that stability held equally among patients with known metastatic disease, four of five lesions, and patients without metastases, 21 of 23 lesions. Metastatic lesions in bone, by contrast, typically evolve, intensifying as disease progresses or fading in response to therapy, particularly during the flare phenomenon that follows effective treatment.

Magnetic resonance imaging provided a second, complementary line of evidence. Within 14 days of their bone scans, 31 patients underwent orbital MRI, which detected abnormal orbital lesions in 16 patients, corresponding to 16 lesions with a mean size of 9.0 plus or minus 2.4 millimeters. The frontal bone was involved in ten cases and the zygomatic bone in six, once again mirroring the superior and lateral orbital walls highlighted on scintigraphy. When the researchers applied the Bone Reporting and Data System, a structured classification scheme designed to standardize the risk assessment of bone lesions, 12 of these lesions fell into the low-concern category 2 or 3, while four were assigned to the more worrisome category 4. Follow-up MRI in 11 lesions showed no change in size over time, although two lesions did display evolution in their signal characteristics, a reminder that even ostensibly benign orbital lesions deserve at least individualized attention rather than reflexive dismissal.

It was computed tomography, however, that emerged as the decisive diagnostic tool. In 21 patients who underwent CT or fluorine-18 FDG PET/CT at a median interval of eight months from the index bone scan, CT identified abnormal orbital findings in 20 patients, totaling 21 foci. Nineteen of those 21 foci, all but one, displayed unambiguously benign features. Eighteen were classified as Bone-RADS category 1, and 16 of these showed the classic ground-glass opacity, a hazy, milky pattern of mineralization that radiologists regard as a near-signature of fibrous dysplasia, a developmental benign bone lesion in which normal marrow is replaced by a fibrous tissue woven with immature trabeculae. Two further foci were lucent lesions of Bone-RADS category 2 or 3. The single exception was an osteolytic lesion of the sphenoid bone exhibiting cortical destruction, assigned Bone-RADS category 4, with an SUVmax of 5.1 on PET, findings that were interpreted as suggestive of metastasis. That outlier is clinically important: it demonstrates that while the pattern is overwhelmingly benign, the occasional genuine metastasis does hide among these hot spots, and imaging characterization, not assumption, is what separates the two.

The metabolic dimension of the study adds a third layer of reassurance. On fluorine-18 FDG PET/CT, the 20 benign-appearing foci showed minimal fluorodeoxyglucose uptake, with a median maximum standardized uptake value of just 1.4. FDG avidity reflects glucose metabolism, and actively proliferating tumor tissue typically consumes the tracer eagerly, driving SUV values well above the benign threshold. A median SUVmax of 1.4 places these orbital lesions firmly in the metabolically quiet company of normal tissue, consistent with the slow, remodeled bone of fibrous dysplasia rather than the voracious biochemistry of metastatic carcinoma. Taken together, the low metabolic activity, the rounded morphology, the characteristic ground-glass attenuation on CT, and the longitudinal stability across a median follow-up approaching two years form a converging constellation of benignity that is difficult to argue with.

Why does this matter beyond the reading room? Incidental findings have become one of the defining challenges of modern imaging. As scanners grow more sensitive and whole-body protocols more common, radiologists increasingly detect anomalies whose clinical significance is unknown, and each of them triggers a cascade of anxiety, additional testing, cost, and sometimes unnecessary invasive procedures for patients already frightened by cancer diagnoses. Bone scintigraphy is performed millions of times a year worldwide, and if roughly one percent of those scans carry an orbital hot spot, the aggregate burden of uncertainty is substantial. By demonstrating that these foci have a reproducible benign signature, the study converts a source of ambiguity into a pattern that can be recognized, characterized, and, in most cases, safely managed without biopsy or aggressive intervention.

The study also carries a practical methodological lesson about the relative strengths of different imaging modalities. MRI, so exquisitely sensitive to marrow infiltration and soft tissue, proved less definitive for these osseous lesions, and its signal characteristics could even evolve over time in ways that complicate interpretation. CT, by contrast, excelled at characterizing the internal architecture of the bone itself, reliably distinguishing the ground-glass mineralization of fibrous dysplasia from the cortical destruction of malignancy. Combined with the metabolic information from FDG PET, CT offered superior osseous characterization versus MRI in this cohort, a conclusion the authors state explicitly and one that should guide clinicians choosing the most efficient follow-up test for an incidental orbital hot spot.

The Beijing team is careful not to advocate for total neglect. Their conclusion endorses individualized imaging surveillance, an approach tailored to each patient’s cancer history, lesion characteristics, and risk profile, rather than a blanket policy of either reflexive biopsy or reflexive dismissal. The five patients with metastatic disease and the single sphenoid metastasis with cortical destruction underscore that context matters: in a patient with widespread progressive malignancy, an orbital focus demands closer scrutiny than the same focus in a patient with degenerative disease and stable imaging elsewhere. But the central message of the study is clear and, for thousands of future patients, genuinely comforting. The small round light beside the eye on a bone scan is, in the vast majority of cases, not a spreading cancer but a quiet quirk of bone biology, a lesion that has likely sat there harmlessly for years and will still be sitting there, unchanged, years from now. In the high-stakes world of oncological imaging, that kind of evidence-based reassurance is worth its weight in technetium.

Subject of Research: Incidental orbital radionuclide uptake on bone scintigraphy and its benign etiology

Article Title: Benign nature of incidental orbital uptake on bone scintigraphy: insights from multi-modality imaging and follow-up

Article References: Song, L., Guo, N., & Zhang, W. (2026). Benign nature of incidental orbital uptake on bone scintigraphy: insights from multi-modality imaging and follow-up. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02844-9

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02844-9

Keywords: bone scintigraphy, orbital lesions, incidental findings, fibrous dysplasia, Bone-RADS, FDG PET/CT, MRI, SUVmax, metastasis, nuclear medicine, multimodal imaging, ground-glass opacity

The case matters because anaplastic thyroid carcinoma, often abbreviated ATC, does not usually announce its return in the large intestine. According to the report’s authors, the metastatic pattern of ATC typically involves the lungs, and autopsy series have documented a wide but characteristic distribution of secondary deposits. Autopsy findings from 45 cases at a single institution, cited in the report, have helped map where this cancer tends to spread. The gastrointestinal tract, and the colon in particular, sits far outside the usual territory. Earlier literature reviewed by the Spanish team includes reports of well-differentiated thyroid cancer metastasizing to the gastrointestinal system, and a 2025 case report describing an isolated bowel metastasis from undifferentiated thyroid carcinoma, but such events remain vanishingly rare.

The patient’s clinical story, as summarized in the published abstract, began with a diagnosis of ATC that harbored a papillary component, a detail that carries real biological weight. Anaplastic thyroid carcinoma is thought in many cases to arise through dedifferentiation of a pre-existing, better-behaved papillary thyroid cancer, and the coexistence of both components in one tumor is a recognized phenomenon. Molecular testing revealed a BRAF V600E mutation, one of the most frequently encountered genetic alterations in this disease and a target of growing therapeutic interest. At the time of initial treatment, the disease had invaded locally beyond the thyroid, a feature that already placed the patient in a high-risk category.

Management followed the standard aggressive playbook for localized ATC. The patient underwent surgery and, after residual disease was detected, radiotherapy. This multimodal approach reflects the reality that anaplastic thyroid carcinoma rarely surrenders to any single treatment. Surgery aims to remove the bulk of disease, radiotherapy suppresses local regrowth, and in suitable cases targeted drugs directed against mutations such as BRAF V600E may be added. Despite these efforts, ATC carries a dismal prognosis, with median survival measured in months for many patients, which makes a disease-free interval of 17 months in this case notably long.

It was during surveillance after that interval that the colonic lesion appeared. The report emphasizes the role of [18F]FDG PET/CT in making the detection possible. The technique works by exploiting the altered metabolism of cancer cells. Fluorodeoxyglucose is a radioactive analog of glucose that is taken up by metabolically active tissue, and most malignant tumors, being hungry for glucose, accumulate the tracer avidly. The positron emission tomography component maps where the tracer concentrates throughout the body, while the computed tomography component provides detailed anatomical context, allowing physicians to pinpoint exactly which organ or structure is lighting up.

For thyroid cancer specifically, this imaging strategy has a particular logic. Well-differentiated thyroid cancers are traditionally followed with radioactive iodine imaging, because they retain the iodine-handling machinery of normal thyroid tissue. But as tumors dedifferentiate, they lose that machinery and simultaneously tend to become more glycolytically active, meaning they take up more glucose. Anaplastic thyroid carcinoma represents the extreme end of this spectrum: it is typically iodine-avid not at all and glucose-avid to a striking degree. That metabolic profile makes [18F]FDG PET/CT one of the most informative tools available for detecting ATC recurrence and spread, especially in atypical locations where conventional surveillance might not think to look.

The histological confirmation of the colonic lesion as an ATC metastasis is the linchpin of the report. Distinguishing a metastasis from thyroid carcinoma in the bowel from a primary colorectal cancer is not trivial, and it requires careful pathological analysis, often aided by immunohistochemical markers and knowledge of the patient’s molecular profile, including the BRAF V600E mutation found in the original tumor. The confirmation transforms what might have been dismissed as an unrelated second cancer into evidence of disseminated disease, with immediate consequences for staging, prognosis, and treatment planning.

The clinical lesson the authors draw is straightforward but consequential: unusual presentations demand imaging capable of surveying the whole body. A patient treated for anaplastic thyroid carcinoma who develops gastrointestinal symptoms, or an incidental finding on any scan, should prompt clinicians to consider metastatic disease even in organs far from the typical metastatic map. Because ATC is so aggressive and its treatment options narrow once disease spreads, early detection of an atypical recurrence can change the trajectory of care, opening doors to localized therapies, systemic targeted treatment, or enrollment in clinical trials that would be inappropriate if the recurrence went unrecognized.

The broader context underscores why vigilance matters. Thyroid cancer as a whole is common and, in its differentiated forms, highly curable, with long-term survival exceeding the vast majority of solid tumors. Reviews published in JAMA and The Lancet in 2023 and 2024, cited in the report, frame the disease as a spectrum ranging from indolent nodules to one of medicine’s fastest killers. Anaplastic carcinoma accounts for only a small fraction of thyroid malignancies but a disproportionate share of thyroid cancer deaths. Its tendency for rapid local invasion and distant spread means that surveillance strategies, molecular profiling, and whole-body functional imaging all play interlocking roles in managing the disease.

For the nuclear medicine community, the case is a compact demonstration of the value of [18F]FDG PET/CT beyond routine indications. Published as an Image of the Month, it joins a small but growing literature on gastrointestinal metastases from thyroid carcinoma, including a documented case in which small bowel perforation and death were caused by an ATC metastasis in a patient with concurrent colonic and bilateral breast cancers. Each such report expands the collective awareness of where this relentless cancer can hide. The Barcelona team, led by Marta Argelés Colet and colleagues, received no external funding for the work and declared no conflicts of interest, and the case was managed in accordance with the principles of the Declaration of Helsinki. As targeted therapies against BRAF-mutant disease mature and imaging technology sharpens, the hope is that unusual recurrences like this one will be caught earlier, when something can still be done about them.

Subject of Research: Detection of an unusual colonic metastasis from anaplastic thyroid carcinoma using FDG PET/CT

Article Title: Colonic metastasis from anaplastic thyroid carcinoma: The value of [18F]FDG PET/CT in an unusual presentation

Article References: Colonic metastasis from anaplastic thyroid carcinoma: The value of [18F]FDG PET/CT in an unusual presentation. (n.d.). https://doi.org/10.1007/s00259-026-08193-7

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08193-7

Keywords: anaplastic thyroid carcinoma, FDG PET/CT, colonic metastasis, BRAF V600E, thyroid cancer, nuclear medicine, cancer imaging, metastasis, molecular imaging, radiotherapy, case report, gastrointestinal metastasis

Renal cell carcinoma ranks as the seventh most common malignant tumor in men and the tenth most common in women worldwide. Roughly one in four to one in three patients already harbor distant metastases when they are first diagnosed, with the disease seeding most frequently into regional lymph nodes, lungs, bones, and liver. Yet the bladder is an extraordinarily uncommon destination. Fewer than seventy cases of bladder metastasis from renal cell carcinoma have ever been reported in the medical literature, and virtually none have described this pattern emerging after a patient had already undergone radical nephrectomy, metastasectomy, and multiple lines of targeted therapy. That is precisely what makes this new case, published in Clinical Case Reports by clinicians at the First Affiliated Hospital of Zhejiang University School of Medicine, so noteworthy.

The technical details of the initial diagnosis illustrate how modern imaging dissects a renal mass. Contrast-enhanced computed tomography showed the tumor lighting up intensely during the arterial phase, a signature of the rich, disordered blood supply that characterizes clear cell carcinoma, while uneven enhancement pointed to localized ischemic necrosis deep within the lesion. These findings ruled out the principal differential diagnoses, including renal tuberculosis, kidney stones, renal cysts, and hamartomas, and staged the disease as T4N0M1, meaning a locally advanced primary tumor with distant metastatic involvement but no lymph node spread. Surgeons proceeded with a laparoscopic radical left nephrectomy, and pathology under the microscope confirmed clear cell renal cell carcinoma.

Because the disease was already metastatic at diagnosis, the oncology team initiated adjuvant systemic therapy with sunitinib, a tyrosine kinase inhibitor delivered at fifty milligrams daily. Sunitinib has historically been a cornerstone of first-line treatment, with landmark trials demonstrating significantly prolonged overall survival compared with interferon alpha. In this patient, however, the drug failed. Within three months, follow-up CT scans showed clear progression of the metastasis in the right adrenal gland. Surgeons removed the gland, pathology again confirming infiltration by clear cell carcinoma, and the team switched to a second tyrosine kinase inhibitor, axitinib at five milligrams twice daily, with imaging every three months. The message was already becoming unmistakable: this tumor was proving refractory to the standard pharmacological arsenal.

Ten months after the original surgery, the patient developed pain in her right thumb. Hand CT imaging revealed osteolytic bone destruction, a hole eaten into the base of the first metacarpal by metastatic cells, with associated soft tissue involvement. Surgeons resected the metastatic bone tumor, reconstructed the defect with a bone graft, and fixed it internally. Pathology confirmed clear cell renal cell carcinoma metastasis. One week later, a whole-body F-18 FDG PET/CT scan was performed, and the results expanded the map of the disease dramatically: the tracer lit up metastatic deposits in the skull, and, remarkably, in the bladder.

Cystoscopy, the direct visual inspection of the bladder interior, revealed two red neoplastic lesions on the bladder wall. Transurethral resection removed the tissue, and histopathological examination confirmed the stunning diagnosis: metastatic clear cell renal cell carcinoma growing inside the bladder, entirely asymptomatic. This last point carries real clinical weight. According to prior literature, roughly seventy percent of patients with bladder metastasis from renal cell carcinoma present with hematuria, visible blood in the urine. This patient had none. Her bladder metastasis was found purely incidentally on PET imaging, a discovery that would likely have been delayed, perhaps indefinitely, in a less thoroughly monitored patient.

Facing relentless progression, the clinicians escalated to combination therapy, pairing axitinib with toripalimab, an immune checkpoint inhibitor, at 240 milligrams. The rationale rested on recent phase III evidence from the RENOTORCH trial, which demonstrated that the combination of toripalimab and axitinib delivered superior clinical benefit compared with sunitinib monotherapy as first-line treatment for advanced renal cell carcinoma. The combination appeared to achieve local control where it mattered most in this case: after transurethral resection of the bladder tumor, follow-up cystoscopic examinations showed no evidence of bladder tumor recurrence, even after a full year of continuous combination therapy. Yet the systemic disease refused to stand still. Three months before the report was finalized, routine abdominal CT revealed new metastatic lesions in the right ninth rib and in the bilateral iliac bones of the pelvis, signaling that distant skeletal spread was continuing despite the intensified regimen.

The trajectory of this case underscores a sobering paradox in contemporary kidney cancer treatment. Targeted therapy and immunotherapy have genuinely transformed outcomes in advanced renal cell carcinoma, extending survival in large prospective clinical trials and converting what was once an almost uniformly fatal diagnosis into a chronic disease for many patients. Prolonged survival, however, creates a longer window in which the biology of the tumor can express itself in unusual ways, and clinicians are increasingly reporting metastases to rare sites such as the esophagus, the eyeball, and now the bladder. Previous case reports of bladder metastasis typically described patients with localized renal tumors who developed isolated bladder recurrence several years after partial or radical nephrectomy, without disease elsewhere, or involved non-classical histological subtypes. No previous report, as far as the authors know, had documented bladder metastasis in advanced renal cell carcinoma developing after first-line targeted therapy in a patient with widespread systemic disease.

Over the course of her care, this patient underwent five salvage tumor resections, including the nephrectomy, adrenalectomy, metacarpal resection, cranial metastasis resection, and transurethral bladder tumor resection, alongside continuously evolving systemic therapy. The authors emphasize that resecting bladder metastases may reduce local recurrence but cannot suppress distant spread, and that there is currently no standardized clinical guideline for managing bladder metastasis of renal cell carcinoma at all. For patients like this one, who remain refractory to first-line and second-line regimens and continue to accumulate metastases, the authors argue that genomic profiling to identify novel therapeutic targets may offer the next realistic avenue of clinical benefit. The patient remains under active follow-up, generally stable in condition even as her bone metastases progress, and her treatment regimen is expected to require further adjustment.

The broader lesson for clinicians and researchers alike is vigilance. Bladder metastasis of renal cell carcinoma is rare enough to escape suspicion, and its frequent association with hematuria means an asymptomatic presentation, as in this case, could easily evade detection without systematic PET/CT surveillance and cystoscopic confirmation. As targeted agents and immune checkpoint inhibitors continue to extend the lives of patients with metastatic kidney cancer, the population of long-term survivors will grow, and with it the likelihood that oncologists will encounter metastatic patterns that current guidelines never anticipated. This single patient’s two-year journey, from an incidental ultrasound finding to a bladder seeded with kidney cancer that never once bled, is a vivid reminder that in advanced clear cell renal cell carcinoma, the map of metastasis is still being drawn, and every unusual case redraws it a little further.

Subject of Research: A rare case of asymptomatic bladder metastasis from advanced clear cell renal cell carcinoma following radical nephrectomy, metastasectomy, and targeted and immunotherapy.

Article Title: Metastatic Clear Renal Cell Carcinoma in Bladder Following Radical Nephrectomy, Metastasectomy, and Targeted Therapy: A Rare Case Report

Article References: Zheng, X., Jiang, P., & Zhou, J. (2026). Metastatic Clear Renal Cell Carcinoma in Bladder Following Radical Nephrectomy, Metastasectomy, and Targeted Therapy: A Rare Case Report. Clinical Case Reports, 14(9), Article e73557. https://doi.org/10.1002/ccr3.73557

Image Credits: AI Generated

DOI: 10.1002/ccr3.73557

Keywords: clear cell renal cell carcinoma, bladder metastasis, radical nephrectomy, sunitinib, axitinib, toripalimab, tyrosine kinase inhibitor, immunotherapy, bone metastasis, FDG PET/CT, cystoscopy, case report